Shots:
- UCB has entered into a definitive agreement to acquire Candid Therapeutics, expanding its immunology pipeline with novel T-cell engagers (TCE)
- As per the deal, UCB will acquire Candid for $2B upfront & ~$200M in potential future milestone payments; closing is expected by end of Q2 or early Q3’26
- Acquisition will add cizutamig, a BCMA T-cell engager targeting BCMA & CD3 on T-Cells for autoimmune diseases, which is under evaluation in >10 indications, along with Candid’ multi-specific TCE pipeline for targeted B-cell depletion & immune reset
Ref: Businesswire | Image: Candid |Press Release
Related News: UCB to Acquire Neurona Therapeutics for ~$1.15B, Expanding into Regenerative Epilepsy Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
